Anti-B7-H4 antibodies and immunoconjugates

Patent Citations (182)

Non-Patent Literature (155)

• Choi et al., “Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family” J Immunol 171(9):4650-4654 (Nov. 1, 2003).Applicant
• File history of U.S. Appl. No. 14/207,878, (filed Mar. 13, 2014).Applicant
• International Search Report and Written Opinion for International Application No. PCT/US2014/025285 filed Mar. 13, 2014, pp. 13 (mailed Jun. 26, 2014).Applicant
• Leong et al., “An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer” Molecular Pharmaceutics 12(6):1717-1729 (Apr. 8, 2015).Applicant
• Sica et al., “B7-H4, a molecule of the B7 family, negatively regulates T cell immunity” Immunity 18(6):849-861 (Jun. 2003).Applicant
• International Search Report and Written Opinion for PCT Application No. PCT/US2015/049551, pp. 21 (mailed Feb. 16, 2016).Applicant
• File History for U.S. Appl. No. 14/851,003, (filed Sep. 11, 2015).Applicant
• File History for U.S. Appl. No. 14/773,334, (371(c) date Sep. 5, 2015).Applicant
• Ajani et al., “A Multi-Institutional Phase II Study of BMS-182248-01 (BR96-Doxorubicin Conjugate) Administered Every 21 Days in Patients with Advanced Gastric Adenocarcinoma” Cancer Journal 6:78-81 ( 2000).Applicant
• Alley, S.C. et al., “Controlling the location of drug attachment in antibody-drug conjugates, Abstract No. 627, American Association for Cancer Research, 2004 Annual Meeting, Mar. 27-31, 2004 Proceedings of the AACR” 45:52 (2004).Applicant
• Almagro et al., “Humanization of antibodies” Frontiers in Bioscience 13:1619-1633 (Jan. 2008).Applicant
• Antonow et al., “Structure-Activity Relationships of Monomeric C2-Aryl Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Antitumor Agents” J Med Chem(53):2927-2941 ( 2010).Applicant
• Baca et al., “Antibody humanization using monovalent phage display” J Biol Chem 272(16):10678-10684 ( 1997).Applicant
• Boerner et al., “Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes” J Immunol 147(1):86-95 (Jul. 1991).Applicant
• Brennan et al., “Preparation of Biospecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments” Science 229(4708):81-83 (Jul. 5, 1985).Applicant
• Bruggemann et al., “Comparison of the Effector Functions of Human Immunogobulins Using a Matched set of Chimeric Antibodies” Journal Exp. Med. 166:1351-1361 ( 1987).Applicant
• Bubendorf et al., “Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies” J Pathol 195:72-79 ( 2001).Applicant
• Carter et al., “Humanization of an anti-p185 HER2 antibody for human cancer therapy” P Natl Acad Aci USA 89:4285-4289 (May 1992).Applicant
• Chari et al., “Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs” Cancer Research 52:127-131 ( 1992).Applicant
• Chari, “Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs” Accounts of Chemical Research 41(1):98-107 ( 2008).Applicant
• Chen et al., “Selection and anlysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen” J Mol Biol 293(4):865-881 (Nov. 5, 1999).Applicant
• Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins” J Mol Biol 196:901-917 ( 1987).Applicant
• Chowdhury, “Engineering hot spots for affinity enhancement of antibodies” Methods Molec Biol 207:179-196 ( 2008).Applicant
• Clackson et al., “Making antibody fragments using phage display libraries” Nature 352:624-628 (Aug. 15, 1991).Applicant
• Clynes et al., “Fc receptors are required in passive and active immunity to melanoma” P Natl Acad Sci USA 95(2):652-656 (Jan. 1998).Applicant
• Cragg et al., “Antibody Specificity Controls in Vivo Effector Mechanisms of Anti-CD20 Regents” Blood 103:2738-2743 ( 2004).Applicant
• Cragg, M.S. et al., “Complement-Mediated Lysis by Anti-CD20 mAb Correlates wirh Segregation into Lipid Rafts” Blood 101(3):1045-1051 ( 2003).Applicant
• Cree et al., “Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay” Anticancer Drugs 6:398-404 ( 1995).Applicant
• Cunningham and Wells, “High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis” Science 24:1081-1085 (Jun. 2, 1989).Applicant
• Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy” Nat Biotechnol 21(7):778-784 (Jul. 2003).Applicant
• Doronina et al., “Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity” Bioconjug Chem 17(1):114-124 (Jan. 2006).Applicant
• Dubowchik et al., “Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages” Bioorg Med Chem Lett 12:1259-1532 ( 2002).Applicant
• Duncan and Winter, “The Binding Site for Clq on IgG” Nature 332:738-740 (Apr. 21, 1988).Applicant
• Fellouse et al., “Synthetic antibodies from a four-amino-acid code: A dominant role for tyrosine in antigen recognition” P Natl Acad Sci USA 101(34):12467-12472 (Aug. 24, 2004).Applicant
• Flatman et al., “Process analytics for purification of monoclonal antibodies” Chromatography B 848:79-87 ( 2007).Applicant
• Foote et al., “Antibody Framework Residues Affecting the Confirmation of the Hypervariable Loops” J Mol Biol 224:487-499 ( 1992).Applicant
• Gazzano-Santoro et al., “A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody” J Immunol Methods 202:163-171 ( 1997).Applicant
• Geoghegan and Stroh, “Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to Modification N-terminal serine” Bioconjugate Chem. 3:138-146 ( 1992).Applicant
• Gerngross, “Advances in the Production of Human Therapeutic Proteins in Yeasts and Filamentous Fungi” Nat. Biotech. 22:1409-1414 ( 2004).Applicant
• Graham et al., “Characteristics of a Human Cell Line Transformed by DNA form Human Adenovirus Type 5” J. Gen. Virol. 36:59 ( 1977).Applicant
• Grandi et al., “Novel anthracycline analogs” Cancer Treatment Reviews 17:133-138 ( 1990).Applicant
• Griffiths et al., “Human anti-self antibodies with high specificity from phage display libraries” EMBO J 12(2):725-734 (Feb. 1993).Applicant
• Gruber et al., “Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli” J Immunol 152:5368-5374 ( 1994).Applicant
• Guyer et al., “Immunoglobulin binding by mouse intestinal epithelial cell receptors” J Immunol 117(2):587-593 (Aug. 1976).Applicant
• Hamann, “Monoclonal antibody—drug conjugates” Expert Opin Ther Patents 15(9):1087-1103 ( 2005).Applicant
• Hamblett et al., (‘Effect of drug loading on the pharmacology, pharmacokinetics and toxicity of an anti-CD30 antibody-drug conjugate, Abstract No. 624, American Association for Cancer Research; 2004 Annual Meeting, Mar. 27-31, 2004, Proceedings of the AACR’ 45:52 (2004)).Applicant
• Hamblett et al., “Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate” Clin Cancer Res 10:7063-7070 ( 2004).Applicant
• Hartley et al., “SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity” Cancer Res. 70(17):6849-6858 ( 2010).Applicant
• Hellstrom et al., “Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas” P Natl Acad Sci USA 83:7059-7063 (Sep. 1986).Applicant
• Hellstrom et al., “Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside” P Natl Acad Sci USA 82:1499-1502 (Mar. 1985).Applicant
• Hinman et al., “Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics” Cancer Res 53:3336-3342 ( 1993).Applicant
• Hollinger et al., Proceedings of the National Academy of Sciences 90:6444-6448 (Jul. 1993).Applicant
• Holmes et al., “Identification of Heregulin, A Specific Activator of p185\\\superscript:erbB2\\\” Science 256:1205-1210 (May 22, 1992).Applicant
• Hoogenboom et al., “By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro” J Mol Biol 227(2):381-388 (Sep. 1992).Applicant
• Hoogenboom et al., “Overview of antibody phage-display technology and its applications” Methods Mol Biol 178:1-37 ( 2002).Applicant
• Howard et al., “Synthesis of a novel C2/C2′-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate” Bioorg Med Chem Lett 19(22):6463-6466 ( 2009).Applicant
• Hudson et al., “Engineered antibodies” Nature Medicine 9(1):129-134 (Jan. 2003).Applicant
• Hurley et al., “Covalent Binding of Antitumor Antibiotics in the Minor Groove of DNA. Mechanism of Action of CC-1065 and the Pyrrolo(1,4)benzodiazepines” Acc Chem Res 19:230-237 ( 1986).Applicant
• Idusogie et al., “Mapping of the C1q Binding Site on Rituxan, A Chimeric Antibody with a Human IgG1 Fc” J Immunol 164(8):4178-4184 ( 2000).Applicant
• Jeffrey et al., “Dipeptide-based highly potent doxorubicin antibody conjugates” Bioorganic & Medicinal Chemistry Letters 16:358-362 ( 2006).Applicant
• Kam et al., “Carbon nanotubes as multifunctional biological transporters and near-infared agents for selective cancer cell destruction” PNAS 102(33):11600-11605 (Aug. 16, 2005).Applicant
• Kanda et al., “Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC” Biotechnol Bioeng 94(4):680-688 (Jul. 5, 2006).Applicant
• Kashmiri et al., “SDR grafting—a new approach to antibody humanization” Methods :36:25-34 ( 2005).Applicant
• Kim et al., “Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor” Eur J Immunol 24:2429-2434 ( 1994).Applicant
• Kinet et al., “Fc receptors” Annu Rev Immunol. 9:457-92 ( 1991).Applicant
• King et al., “Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: Inhibition of aggregation by methoxytriethyleneglycol chains” Journal of Medical Chemistry 45:4336-4343 ( 2002).Applicant
• Klimka et al., “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning” Brit J Cancer 83(2):252-260 ( 2000).Applicant
• Kostelny et al., “Formation of a bispecific antibody by the use of leucine zippers” 148:1547-1553 (Mar. 1, 1992).Applicant
• Kozbor et al., “A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies” J Immunol 133(6):3001-3005 (Dec. 1, 1984).Applicant
• Kratz et al., “Prodrugs of anthracyclines in cancer chemotherapy” Curr Med Chem:13:477-523 ( 2006).Applicant
• Lee et al., “Bivalent antibody phage display mimics natural immunoglobulin” J immunol Methods 284(1-2):119-132 ( 2004).Applicant
• Lee et al., “High-affinity human antibodies from a phage-displayed synthetic Fab libraries with a single framework scaffold” J Mol Biol 340(5):1073-1093 ( 2004).Applicant
• Leimgruber et al., “Isolation and characterization of anthramycin, a new antitumor antibiotic” J Am Chem Soc 87(24):5791-5793 ( 1965).Applicant
• Leimgruber et al., “The structure of anthramycin” J Am Chem Soc 87(24):5793-5795 ( 1965).Applicant
• Li et al., “Human antibodies for immunotherapy development generated via a human B cell hybridoma technology” P Natl Acad Sci USA 103(10):3557-62 (Mar. 2006).Applicant
• Li et al., “Optimization of humanized IgGs in glycoengineered Pichia pastoris” Nat Biotechnol 24(2):210-215 (Feb. 2006).Applicant
• Liu et al. et al., “Eradication of large colon tumor xenografts by targeted delivery of maytansinoids” P Natl Acad Sci USA 93(16):8618-8623 (Aug. 6, 1996).Applicant
• Lode et al., “Targeted therapy with a novel enediyene antibiotic calicheamicin V11 effectively suppresses growth and dissemination of liver metastases in syngeneic model of murine neuroblastoma” Cancer Res 58:2925-2928 ( 1998).Applicant
• Lonberg, “Fully human antibodies from transgenic mouse and phage display platforms” Current Opin Immunol 20:450-459 ( 2008).Applicant
• Lonberg, N., “Human antibodies from transgenic animals” Nat Biotechnol 23(9):1117-11125 ( 2005).Applicant
• Lyon et al., “Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues” Methods Enzymol 502:123-138 ( 2012).Applicant
• MacCallum et al. et al., “Antibody-antigen interactions: contact analysis and binding site topography” J Mol Biol 262(5):732-745 (Oct. 11, 1996).Applicant
• Mandler et al., “Immunoconjugates of geldanamycin and Anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines” J National Cancer Institute 92(19):1573-1581 (Oct. 4, 2000).Applicant
• Mandler et al., “Modifications in synthesis strategy improve the yield and efficacy of geldanamycin—herceptin immunoconjugates” Bioconjugate Chem 13:786-791 ( 2002).Applicant
• Mandler et al., “Synthesis and evaluation of antiproliferative activity of a Geldanamycin-Herceptin\\\superscript:™\\\immunoconjugate” Bioorg Med Chem Lett 10:1025-1028 ( 2000).Applicant
• Marks et al., “Selection of Human Antibodies from Phage Display Libraries” Methods in Molecular Biology 248:161-176 ( 2003).Applicant
• Mather et al., “Culture of testicular cells in hormone-supplemented serum-free medium” Ann NY Acad Sci 383:44-68 ( 1982).Applicant
• Mather “Establishment and characterization of two distinct mouse testicular epithelial cell lines” Biol Reprod 23:243-252 ( 1980).Applicant
• McCafferty et al., “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains” Nature 348:552-554 (Dec. 1990).Applicant
• Milstein and Cuello, “Hybrid hybridomas and their use in immunohistochemistry” Nature 305:537-540 (Oct. 6, 1983).Applicant
• Morrison et al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains” P Natl Acad Sci USA 81:6851-6855 (Nov. 1984).Applicant
• Nagy et al., “Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies” P Natl Acad Sci USA 97(2):829-34 (Jan. 18, 2000).Applicant
• Neuberger et al., “Recombinant Antibodies Possessing Novel Effector Functions” Nature 312:604-608 (Dec. 13, 1984).Applicant
• Okazaki et al., “Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa” J Mol Biol 336(5):1239-1249 (Mar. 5, 2004).Applicant
• Osbourn et al., “From rodent reagents to human therapeutics using antibody guided selection” Methods 36:61-68 ( 2005).Applicant
• Pacciarini et al., “Phase I/II trial of nemorubicin hydrochloride in combination with cisplatin is supported by new preclinical evidences of its mechanism of action” J Clin Oncol (Abstract from 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition)), 24(Suppl 18S):14116 (Jun. 20, 2006).Applicant
• Padlan, “A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties” Mol Immunol 28(4/4):489-498 ( 1991).Applicant
• Petkova et al., “Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease” Int Immunol 18(12):1759-69 (Dec. 2006).Applicant
• Pettit et al., “Antineoplastic agents 365. Dolastatin 10 SAR probes” Anti-Cancer Drug Design 13:243-277 ( 1998).Applicant
• Pettit et al., “Dolastatins 24: synthesis of (-)-dolastatin 10. \\\superscript:1\\\ X-ray molecular structure of N,N-dimethylvalyl-valyl-dolaisoleuine tert-butyl ester” J Chem Soc Perkins Trans 1:859-863 ( 1996).Applicant
• Pettit et al., “The absolute configuration and synthesis of natural (-)-Dolastatin 10\\\superscript:1\\\” J Am Chem Soc 111:5463-5465 ( 1989).Applicant
• Pettit et al., “The dolastatins; 18: stereospecific synthesis of dolaproine” Synthesis:719-725 (Jun. 1996).Applicant
• Polakis, “Arming antibodies for cancer therapy” Curr Opin Pharm 5:382-387 ( 2005).Applicant
• Portolano et al., “Lack of promiscuity in autoantigen-specific H and L chain combinations as revealed by human H and L chain ‘roulette’” J Immunol 150(3):880-7 (Feb. 1, 1993).Applicant
• Presta et al., “Humanization of an Antibody Directed Against IgE” J Immunol 151(5):2623-2632 (Sep. 1, 1993).Applicant
• Presta et al., “Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders” Cancer Res 57(20):4593-4599 (Oct. 15, 1997).Applicant
• Queen et al., “A humanized Antibody that Binds to the Interleukin 2 Receptor” P.N.A.S. USA 86:10029-10033 ( 1989).Applicant
• Quintieri et al., “Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes” Clin Cancer Res 11:1608-17 (Feb. 15, 2005).Applicant
• Quintieri et al., “In vitro cytotoxicity, cell cycle effects and DNA-binding properties of PNU-159682” Abstract (Abs #4649) Proceedings of the American Association of Cancer Research, pp. 925 (2003).Applicant
• Riechmann et al., “Reshaping Human Antibodies for Therapy” Nature 332(24):323-327 (Mar. 24, 1988).Applicant
• Ripamonti et al., “In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells” Br J Cancer 65(5):703-707 ( 1992).Applicant
• Ripka et al., “Two chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose” Arch Biochem Biophys 249(2):533-545 (Sep. 1986).Applicant
• Rosok et al., “A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab” J Biol Chem 271(37):22611-22618 (Sep. 13, 1996).Applicant
• Saleh et al., “Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors” J Clin Oncol 18(11):2282-2292 ( 2000).Applicant
• Shields et al. et al., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R” J Biol Chem 276(9):6591-6604 (Mar. 2, 2001).Applicant
• Sidhu et al., “Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions” J Mol Biol 338(2):299-310 ( 2004).Applicant
• Sims et al., “A Humanized CD18 Antibody Can Block Function Without Cell Destruction” J Immunol 151(4):2296-2308 (Aug. 15, 1993).Applicant
• Storm et al., “Effect of small changes in orientation on reaction rate” J Am Chem Soc 94:5815-5825 ( 1972).Applicant
• Sun et al., “Enabling ScFvs as multi-drug carriers: a dendritic approach” Bioorg Med Chem 11:1761-1768 ( 2003).Applicant
• Teicher, “Antibody-Drug Conjugate Targets” Current Cancer Drug Targets 9:982-1004 ( 2009).Applicant
• Thurston and Bose, “Synthesis of DNA-Interactive Pyrrolo[2,1-c][1,4]benzodiazepines” Chem Rev 94:433-465 ( 1994).Applicant
• Tolcher et al., “Randomized phase II study of BR96-doxorubicin conjugate in patients metastatic breast cancer” J Clin Oncol 17(2):478-484 ( 1999).Applicant
• Torgov et al., “Generation of an intensely potent anthracycline by a monoclonal antibody-(beta)-galactosidase conjugate” Bioconjugate Chemistry 16:717-721 ( 2005).Applicant
• Traunecker et al., “Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells” EMBO J 10(12):3655-3659 ( 1991).Applicant
• Tutt et al., “‘Trispecific F(ab’)3 Derivatives that Use Cooperative Signaling Via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells” J Immunol 147(1):60-69 (Jul. 1991).Applicant
• Urlaub et al., “Isolation of chinese hamster cell mutants deficient in dihydrofolate reductase activity” P Natl Acad Sci USA 77(7):4216 (Jul. 1980).Applicant
• van Dijk and van de Winkel, “Human antibodies as next generation therapeutics” Curr Opin Chem Biol 5(4):368-74 (Aug. 2001).Applicant
• Van Dongen et al., “Immuno-PET: A navigator in monoclonal antibody development and applications” Oncologist 12:1379-1389 ( 2007).Applicant
• Verel et al., “\\\superscript:89\\\Zr Immuno-PET: Comprehensive Procedures for the production of \\\superscript:89\\\Zr-labeled monoclonal antibodies” J Nucl Med 44(8):1271-1281 (Aug. 2003).Applicant
• Vollmers and Brandlein, “The ‘early birds’: Natural IgM antibodies and immune surveillance” Histol Histopathol 20:927-937 ( 2005).Applicant
• Widdison et al., “Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer” J Med Chem 49:4392-4408 ( 2006).Applicant
• Winter et al., “Making antibodies by phage display technology” Annu Rev Immunol 12:433-455 ( 1994).Applicant
• Woyke et al., “In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE” Antimicrob Agents Chemother 45(12):3580-3584 (Dec. 2001).Applicant
• Wright et al., “Effect of glycosylation on antibody function: implications for genetic engineering” Trends Biotechnol. 15(1):26-32 ( 1997).Applicant
• Yamane-Ohnuki et al., “Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity” Biotechnol Bioeng 87(5):614-622 (Sep. 5, 2004).Applicant
• Amsberry and Borchardt, “The Lactonization of 2′-Hydroxy Hydrocinnamic Acid Amides: A Potential Prodrugs for Amines” J. Org. Chem 55(23):5867-5877 (1990).Applicant
• Carter and Senter, “Antibody-drug Conjugates for Cancer Therapy” Cancer J. 14:154-169 (2008).Applicant
• Crouch et al., “The use of the ATP bioluminescence as a measure of cell proliferation and cytotoxicity” J. Immunol Methods 160:81-88 (1993).Applicant
• Dall'Acqua et al., “Antibody humanization by framework shuffling” Methods 36(1):43-60 (Jan. 17, 2005).Applicant
• Dobowchik and Radia, “Monomethoxytrityl (MMT) as a Versatile Amino Protecting Group for Complex Prodrugs on Anticancer Compounds Sensitive to Strong Acids, Bases and Nucleophiles” Tetrahedron Lett 38(30):5257-5260 (1997).Applicant
• Fraker and Speck, “Protein and Cell Membrane Iodinations with a Sparingly Soluble Chloroamide, 1, 3, 4, 5-Tetrachloro-3a, 6a-Diphenylglycoluril” Biochem Biophsic Res Commun 80(4) (Feb. 28, 1978).Applicant
• Francisco et al., “cAC10-vcMMAE, and anti-CD30-monomethly auristatin E conjugate with potent and selective antitumor activity” Blood 102(4):1458-1465 (Aug. 15, 2003).Applicant
• Frisch et al., “Synthesis of Short Polyoxyethelene-Based Heterobifunctional Cross-Linking Reagents. Application to the Coupling of Peptides to Liposomes” Bioconjugate Chem 7(2):180-186 (Feb. 1, 1996).Applicant
• Hay et al. et al., “A 2-Nitroimidazole Carbamate Produrg of 5-Amino-1-(Chloromethyl)-3-[(5,6,7-Trimethoxyindol-2-YL)Carbonyl]- 1,2-Dihydro-3H-Benz-[E]Indole (Amino-Seco-CBI-TMI) for use with Adept and Gdept” Bioorg Med Chem Lett 9:2337-2242 (1999).Applicant
• Kingsbury et al., “A Novel Peptide Delivery System Involving Peptidase Activated Prodrugs as Antimicrobial Agents. Synthesis amd Biological Activity of Peptidyl Derivatives of 5-Fluorouracil” J. Med. Chem. 27(11):1447-1451 (1984).Applicant
• Klussman et al., “Secondary mAb-vcMMAE Conjugates Are Highly Sensitive Reporters of Antibody Internalization via the Lysosome Pathway” Bioconjugate Chem. 15(4):765-773 (Jun. 18, 2004).Applicant
• McDonagh et al., “Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment” Protein Engineering, Design & Selection 19(7):299-307 (Apr. 28, 2006).Applicant
• Pettit et al., “Specific activities of dolastatin 10 and peptide derivatives against Cryptococcus neoformans” Antimicrob. Agents Chemother. 42(11):2961-2965 (Nov. 1985).Applicant
• Rodrigues et al., “Synthesis and Beta-Lactamase-mediated activation of a cephalosporin-taxol prodrug” Chemistry and Biology 2(4):223-227 (Apr. 1995).Applicant
• Suh et al., “Generation and Characterization of B7-H4/B7S1/B7x-Deficient Mice” Mol. Cell. Biol. 26(17):6403-6411 (Sep. 2006).Applicant
• Sun et al., “Syntheses of Dendritic Linkers Containing Chlorambucil REsidues for the Preparation of Antibody-Multidrug Immunoconjugates” Bioorg Med Chem Lee 12(16):2213-2215 (Apr. 19, 2002).Applicant
• Toki et al., “Protease-Mediated Fragmentation of p-Amidobenzyl Ethers: A New Strategy for the Activation of Anticancer Prodrugs” J. Org. Chem. 67(6):1866-1872 (2002).Applicant
• Walker, “A High Yielding Synthesis of N-Alkyl Maleimides Using a Novel Modicication of the Mitsunobu Reaction” J. Org. Chem. 60(16):5352-5355 (1995).Applicant
• Yu et al., “The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum” PNAS 66(12):7968-7973 (Jun. 11, 2002).Applicant
• Zhu et al., “B7-H4—deficient mice display augmented neutrophil-mediated innate immunity” Blood 113(8):1759-1767 (2009).Applicant